<h3>Background:</h3> A main stay treatment of inflammatory arthritis is glucocorticoids (GCs)^[1]. However, long term use of GCs has been associated with an increased risk of fracture, with studies estimating up to 12% of patients having sustained a fracture whilst on GC treatment^[1][2]. <h3>Objectives:</h3> The aim of this study was to determine the prevalence of fractures in a cohort of patients on long term GCs with a diagnosis of inflammatory arthritis. <h3>Methods:</h3> A database of patients with inflammatory arthritis attending the rheumatology department at the Midlands Regional Hospital Tullamore, since 2009, was reviewed. Patients on long term GCs were identified and outpatient summaries were analysed. Data collection included age, sex, diagnosis, vertebral fracture, other fracture sites and osteoporosis treatment. <h3>Results:</h3> As of September 2018, out of the 2118 patients with a diagnosis of inflammatory arthritis 364 were on long term GCs. 10% of patients had reported vertebral fractures on imaging. 36.4% of patients had other types of fractures reported on imaging; 20%, and the most common site of fracture, were wrist fractures. 83.7% of those who suffered from a vertebral fracture were female. 18.2% of those who sustained fractures were not on any osteoporosis treatment. <h3>Conclusion:</h3> The incidence of fracture in our cohort of patients was higher than suggested in previous studies. Furthermore, it highlights the need for patients on long term GCs to be given osteoporosis prevention therapy. <h3>References</h3> [1] Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69:1521–37 [2] Dam Kim, Soo-Kyung Cho, Byeongju Park, Eun Jin Jang, Sang-Cheol Bae and Yoon-Kyoung Sung. The Journal of Rheumatology March 2018, jrheum.170054 <h3>Disclosure of Interests:</h3> None declared